Final KEYNOTE-048 Results With Frontline Pembrolizumab in Recurrent/Metastatic HNSCC

Video
Conference|ASCO Annual Meeting

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses results from the protocol-specified final analysis of the phase III KEYNOTE-048 trial of pembrolizumab (Keytruda) as frontline therapy for recurrent/metastatic head and neck squamous cell carcinoma.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Dr Boland: Updates in GI Cancer From ASCO 2025

Dr Boland: Updates in GI Cancer From ASCO 2025

Sabrina Serani
July 3rd 2025
Article

Discover groundbreaking advancements in GI cancer treatments from ASCO 2025, highlighting innovative therapies and improved patient outcomes.

Read More

QUILT-88 Study: Promising Survival in Pancreatic Cancer

QUILT-88 Study: Promising Survival in Pancreatic Cancer

Jordyn Sava
July 1st 2025
Article

The QUILT-88 study reveals promising survival rates for advanced pancreatic cancer patients using a multimodal treatment approach, combining chemotherapy and immunotherapy.

Read More

Dr Leleu on SC Isatuximab via On-Body Injector in R/R Multiple Myeloma

Dr Leleu on SC Isatuximab via On-Body Injector in R/R Multiple Myeloma

Jordyn Sava
June 25th 2025
Article

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.

Read More

Atezolizumab Efficacy in Cervical Cancer Consistent Irrespective of PD-L1

Atezolizumab Efficacy in Cervical Cancer Consistent Irrespective of PD-L1

Sabrina Serani
June 20th 2025
Article

Read More

Zanzalintinib/Nivolumab Combo Shows Promise in Advanced RCC

Zanzalintinib/Nivolumab Combo Shows Promise in Advanced RCC

Benjamin Saylor
June 14th 2025
Article

The STELLAR-002 study reports promising efficacy and manageable safety for zanzalintinib plus nivolumab in untreated stage 4 RCC patients.

Read More

Ipi/Nivo Combo Extends Survival in Advanced Kidney Cancer

Ipi/Nivo Combo Extends Survival in Advanced Kidney Cancer

Hannah Clarke
June 13th 2025
Article

Read More